BAYER AKTIENGESELLSCHAFT 30/09/2019 08:37 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Not intended for U.S. and UK Media -Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer Número de registro: 282122